Navigating Healthcare Costs in 2026: The Impact of Negotiated Medicare Drug Prices and Policy Changes
2026 will bring a significant divide in healthcare costs for Americans. The implementation of negotiated Medicare drug prices will benefit some individuals by reducing out-of-pocket expenses, while others may face increased costs due to the expiration of Affordable Care Act tax credits and uncertainties surrounding Medicaid coverage. The decisions made by the Biden and Trump administrations have set the stage for this divide, with Medicare beneficiaries expected to see the most immediate benefits from the negotiated drug prices starting in January.
The negotiated drug prices will apply to the 10 most expensive drugs in the Medicare program, including commonly used medications like Eliquis, Xarelto, Jardiance, and Januvia. AARP estimates that out-of-pocket costs for these drugs will decrease by over 50% on average, with projected savings of $1.5 billion for enrollees next year. Additionally, the Inflation Reduction Act has capped annual out-of-pocket prescription drug spending for Medicare beneficiaries at $2,000, providing significant relief for individuals like Tom Howie from Flint, Michigan, who has already experienced the positive impact of these changes.
While the Inflation Reduction Act has brought about positive changes for Medicare beneficiaries, it has also led to some unintended consequences, such as higher list prices for new medications. Drugmakers are adjusting their pricing strategies in response to the legislation, potentially leading to higher initial prices for new drugs. This trend could continue until policy measures are put in place to address the issue, according to experts like Richard Frank from the Brookings Institution.
On the other hand, changes to ACA subsidies and Medicaid funding could result in higher healthcare costs for some individuals. The expiration of enhanced ACA subsidies may lead to significant premium increases for certain individuals, while Medicaid changes under the "One Big Beautiful Bill" could leave low-income adults in coverage gaps in states that have not expanded Medicaid. These changes are expected to have far-reaching implications for access to healthcare and financial stability for many Americans.
Despite the challenges posed by the evolving healthcare landscape, there are potential opportunities for cost savings for individuals not on Medicare. Efforts by the Trump administration to align prescription drug prices with international standards have resulted in lower prices for certain medications through voluntary agreements with pharmaceutical companies. The TrumpRx initiative aims to connect individuals directly to drugmakers' websites for discounted prices, offering some relief for those paying out of pocket for medications.
Looking ahead, there is still hope for Americans on ACA plans if Congress can reach a deal to extend subsidies next year. While Republicans have resisted efforts to extend subsidies, there is a possibility of retroactive subsidies and a new enrollment period to help individuals access affordable healthcare coverage. The future of healthcare costs in the U.S. remains uncertain, but ongoing policy discussions and initiatives could shape the landscape for millions of Americans in the years to come.